NOVARTIS

Novartis reports positive outcomes from Phase IIIB APPULSE-PNH trial of Fabhalta for treating adults with paroxysmal nocturnal haemoglobinuria, showing improved haemoglobin levels and consistent safety profile.

The global epilepsy drugs market, valued at $7 billion in 2022, is projected to reach $9.8 billion by 2032, driven by increasing prevalence and advancements in treatment options. Key players include Novartis AG, GlaxoSmithKline plc, Sanofi, Abbott Laboratories, and UCB S.A., focusing on product approvals and innovations.

Celltrion Inc. receives Health Canada approval for Omlyclo, a biosimilar of Xolair, enabling sales in Canada for allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic idiopathic urticaria.

The article content is not provided for summarization.

GLP-1 drugs like semaglutide and tirzepatide have expanded uses beyond diabetes and weight loss, potentially treating cardiovascular disease, kidney disease, anxiety, depression, and substance use disorder. CRISPR drugs Casgevy for sickle cell disease and β-thalassemia entered the market, though uptake is slow due to complex treatment processes. Protein-folding algorithms by Baker, Hassabis, and Jumper revolutionized biochemical research and pharmaceutical applications. ADCs received significant investment, with firms exploring new linker chemistries. Amylyx Pharmaceuticals pulled an ALS drug after trial failure, continuing research for other uses. Kelly Chibale called for recognizing African scientific potential. Virologists monitored H5N1, mpox, and Marburg outbreaks, with ongoing research and emergency measures. Radiopharmaceuticals saw increased investment and market growth. Evidence suggests vaccines like shingles and flu jabs may protect against dementia.

Scemblix showed superior major molecular response (MMR) rates at 96 weeks vs. investigator-selected TKIs (74.1% vs. 52%) and imatinib (76.2% vs. 47.1%). Scemblix also demonstrated a 15.1% higher MMR rate vs. 2G TKIs (72.0% vs. 56.9%) and maintained a favorable safety profile with fewer grade ≥3 AEs and lower discontinuation rates due to AEs. These results support Scemblix as a standard of care for Ph+ CML-CP patients.

Asciminib (Scemblix) outperformed standard-of-care tyrosine kinase inhibitors in CML, achieving superior major molecular response rates at 96 weeks in the ASC4FIRST trial. The FDA accelerated approval of asciminib was based on 48-week data, and 96-week data further demonstrated its efficacy and safety profile.

The Oncology Market is critical in global healthcare, driven by cancer prevalence, technological advancements, and strategic collaborations. Key players like Daiichi Sankyo, Bayer AG, and others innovate in diagnostics, treatments, and precision medicine. Market growth is fueled by R&D investments, sustainability focus, and consumer awareness. Challenges include regulatory constraints and talent shortages. Technological integrations like AI and IoT enhance patient care and operational efficiency.

Uganda recognized for clinical trial capability, attracting global pharma investment. Trials like Gilead's lenacapavir for HIV prevention show 100% efficacy. Uganda, along with South Africa, Ethiopia, and Nigeria, leads in African medicine development. Access to Medicine Foundation urges more inclusive pharma business models for low-income countries.

The toxoplasmosis treatment drugs market is projected to grow from $3.16 billion in 2023 to $4.18 billion by 2028, driven by rising prevalence, product innovations, and increased healthcare expenditure.